HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

What policies could last - and what could get axed - amid leadership churn at FDA

How new review policies, the use of AI and other recent FDA changes are being impacted by high turnover at the top.

By PharmaVoice · Jul 10, 2026 · via PharmaVoice

This is an aggregated industry headline. Read the full story at PharmaVoice →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlinePharmaVoice
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The Oral GLP-1 Tracker: Lilly's Foundayo launch remains 'muted'
Fierce Pharma is launching the weekly Oral GLP-1 Tracker, leveraging analysts' notes and IQVIA data to monitor…
Jul 11, 2026
The WeekFierceBiotech ↗
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its 'priority asset'
Hansoh Pharmaceutical's pair of much-hyped ADCs continue to justify partner GSK's decision to make them priori…
Jul 11, 2026
FDA’s FY26 PDUFA Hiring Starts at Zero as Backlog Persists from Prior Years
The WeekBriefing
FDA’s FY26 PDUFA Hiring Starts at Zero as Backlog Persists from Prior Years
The FDA reported no new hires under PDUFA VII or BsUFA III for FY26 through June, with FY25 and FY24 hiring go…
Jul 11, 2026